Daniel Yokell
VP Neuro Telix Pharmaceuticals
Daniel Yokell, Pharm.D., RPh is the Vice-President for Theranostic Neuro-Oncology at Telix Pharmaceuticals. He oversees the development of Telix’s TLX-101 (I131 Iodofalan) and TLX-102 (At211 APA) for glioblastoma therapy. Prior to his role at Telix, Dr Yokell spent over 12 years working on radiopharmaceutical development and clinical translation at Massachusetts General Hospital and Harvard Medical School.
Seminars
Wednesday 18th February 2026
Reconsidering the Design of Phase II/III Clinical Trials to Ensure Patients Overcome Challenges with Standard Control Arms for More Streamlined Trials
12:00 pm
- Discussing strategies for molecular profiling and imaging biomarkers to successfully stratify patients for clinical trials
- Exploring innovative control arms using AI and predictive measure to address budget constraints and patient recruitment challenges
- Overcoming current standard of care involving toxic agents such as TMZ that might hinder the potential benefits of novel therapeutics
Tuesday 17th February 2026
Advancing Imaging Techniques to Tackle Challenges Associated with Pseudo-progression & Pseudo-response in Glioblastoma Patients
8:00 am
- Join this workshop to discuss best practices and future innovations in brain imaging to distinguish between pseudo-responses and real changes more effectively in GBMs
- Exploring strategies to avoid serial brain biopsies GBM drug development to accurately assess dose selection and discover new biomarkers without invasive techniques
- Discussing advanced neuroimaging strategies to address the challenges of high glucose uptake in the brain such as novel PET ligands that target GBM metabolic pathways beyond glucose
- Evaluating the RANO assessment in modern GBM trials, focussing on how pseudo-progression and pseudo-responses can confound a drug’s true efficacy
- Exploring novel and complementary assessment methods, such as volumetric analysis, advanced imaging biomarkers, and the integration of iRANO criteria for GBM immunotherapies, that can provide a more accurate and reproducible picture of tumor response
- Addressing the practical challenges of standardizing new methodologies across different clinical sites and the regulatory considerations for their use as primary or secondary endpoints
